Practice updates — pilot openings, methodology releases, source-coverage extensions, engagement signings (announced with consent). A small rail to keep the curious caught up.
A small number of pilot engagements with biotech and pharma teams against live regulatory and commercial questions. Same engagement standard as a paying engagement: scoped, written, reviewer-signed, audit-trailed.
The Discovery Engine now formally publishes the Tier 01 (re-rank) → Tier 02 (analog) → Tier 03 (novel) escalation framework. Same engine, escalating answer; the Tier the engagement runs at depends on the question, not the buyer.
Four published papers in the BB-METH library, three more in draft for Q3 2026 release. Topics: regulatory pathway, target validation, competitive landscape, deal precedent, IP & FTO, failure record, trial-design precedent.
Brioche's full regulatory posture is now documented at the Regulatory page — data-integrity principles, electronic-records framework, software lifecycle conventions, named-reviewer signature on every brief, seven-year audit-trail retention.
Twenty-eight named regulatory and clinical sources continuously refreshed: FDA, EMA, PMDA, MHRA, Health Canada, NMPA, ClinicalTrials.gov, ChEMBL, OpenTargets, UniProt, PDB, USPTO PatentsView, SEC EDGAR, PubMed, GWAS Catalog, plus thirteen more named at the Approach page.